

Florian van Bommel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8463691/publications.pdf>

Version: 2024-02-01

41
papers

7,121
citations

279487

23
h-index

264894

42
g-index

42
all docs

42
docs citations

42
times ranked

6183
citing authors

#	ARTICLE	IF	CITATIONS
1	EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. <i>Journal of Hepatology</i> , 2017, 67, 370-398.	1.8	3,803
2	Peginterferon Alfa-2a, Lamivudine, and the Combination for HBeAg-Positive Chronic Hepatitis B. <i>New England Journal of Medicine</i> , 2005, 352, 2682-2695.	13.9	1,465
3	The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B. <i>Hepatology</i> , 2017, 66, 1444-1453.	3.6	239
4	Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients â€“ FINITE study. <i>Journal of Hepatology</i> , 2017, 67, 918-924.	1.8	230
5	Serum hepatitis B virus RNA levels as an early predictor of hepatitis B envelope antigen seroconversion during treatment with polymerase inhibitors. <i>Hepatology</i> , 2015, 61, 66-76.	3.6	204
6	Eight-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population. <i>Journal of Hepatology</i> , 2018, 68, 1129-1136.	1.8	88
7	Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B. <i>Journal of Hepatology</i> , 2020, 72, 1088-1096.	1.8	75
8	Host and viral factors associated with serum hepatitis B virus RNA levels among patients in need for treatment. <i>Hepatology</i> , 2018, 68, 839-847.	3.6	72
9	Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B. <i>Journal of Hepatology</i> , 2020, 73, 1037-1045.	1.8	69
10	Quantification of large and middle proteins of hepatitis B virus surface antigen (HBsAg) as a novel tool for the identification of inactive HBV carriers. <i>Gut</i> , 2018, 67, 2045-2053.	6.1	66
11	Ten millennia of hepatitis B virus evolution. <i>Science</i> , 2021, 374, 182-188.	6.0	64
12	T-cell exhaustion and residency dynamics inform clinical outcomes in hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2022, 77, 397-409.	1.8	59
13	Serum HBV RNA as a Predictor of Peginterferon Alfa-2a Response in Patients With HBeAg-Positive Chronic Hepatitis B. <i>Journal of Infectious Diseases</i> , 2018, 218, 1066-1074.	1.9	56
14	Prevalence of occult hepatitis C infection in chronic hemodialysis and kidney transplant patients. <i>Journal of Hepatology</i> , 2014, 60, 928-933.	1.8	55
15	An artificial intelligence model to predict hepatocellular carcinoma risk in Korean and Caucasian patients with chronic hepatitis B. <i>Journal of Hepatology</i> , 2022, 76, 311-318.	1.8	48
16	Safety and effectiveness of up to 3 yearsâ€™ bulevirtide monotherapy in patients with HDV-related cirrhosis. <i>Journal of Hepatology</i> , 2022, 76, 464-469.	1.8	48
17	The times they are a-changing â€“ A refined proposal for finite HBV nucleos(t)ide analogue therapy. <i>Journal of Hepatology</i> , 2021, 75, 474-480.	1.8	46
18	Hepatitis B Virus RNA as Early Predictor for Response to Pegylated Interferon Alpha in HBeAg-Negative Chronic Hepatitis B. <i>Clinical Infectious Diseases</i> , 2021, 72, 202-211.	2.9	41

#	ARTICLE	IF	CITATIONS
19	Less can be more: A finite treatment approach for HBeAg-negative chronic hepatitis B. <i>Hepatology</i> , 2018, 68, 397-400.	3.6	36
20	Composition of HBsAg is predictive of HBsAg loss during treatment in patients with HBeAg-positive chronic hepatitis B. <i>Journal of Hepatology</i> , 2021, 74, 283-292.	1.8	35
21	Stopping long-term treatment with nucleos(t)ide analogues is a favourable option for selected patients with HBsAg-negative chronic hepatitis B. <i>Liver International</i> , 2018, 38, 90-96.	1.9	31
22	A case of HBV-induced liver failure in the REEF-2 phase II trial: Implications for finite treatment strategies in HBV "cure"™. <i>Journal of Hepatology</i> , 2022, 77, 245-248.	1.8	29
23	Baseline risk factors determine lack of biochemical response after SVR in chronic hepatitis C patients treated with DAAs. <i>Liver International</i> , 2020, 40, 539-548.	1.9	24
24	Serum hepatitis B virus RNA predicts response to peginterferon treatment in HBeAg-positive chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2020, 27, 610-619.	1.0	21
25	Risks and Benefits of Discontinuation of Nucleos(t)ide Analogue Treatment: A Treatment Concept for Patients With HBeAg-Negative Chronic Hepatitis B. <i>Hepatology Communications</i> , 2021, 5, 1632-1648.	2.0	20
26	Efficacy and Safety of Bulevirtide plus Tenofovir Disoproxil Fumarate in Real-World Patients with Chronic Hepatitis B and D Co-Infection. <i>Pathogens</i> , 2022, 11, 517.	1.2	20
27	Hepatitis B virus RNA decline without concomitant viral antigen decrease is associated with a low probability of sustained response and hepatitis B surface antigen loss. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 314-320.	1.9	19
28	Incremental value of HBcrAg to classify 1582 HBeAg-negative individuals in chronic infection without liver disease or hepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 733-744.	1.9	18
29	Evolution of Adefovir-Resistant HBV Polymerase Gene Variants after Switching to Tenofovir Disoproxil Fumarate Monotherapy. <i>Antiviral Therapy</i> , 2012, 17, 1049-1058.	0.6	15
30	Association of HLA-DPA1 and HLA-DPB1 polymorphisms with spontaneous HBsAg seroclearance in Caucasians. <i>Liver International</i> , 2019, 39, 646-654.	1.9	12
31	Copy number variation and expression of exportin-4 associates with severity of fibrosis in metabolic associated fatty liver disease. <i>EBioMedicine</i> , 2021, 70, 103521.	2.7	11
32	Percutaneous hepatic melphalan perfusion: Single center experience of procedural characteristics, hemodynamic response, complications, and postoperative recovery. <i>PLoS ONE</i> , 2021, 16, e0254817.	1.1	10
33	Glecaprevir/pibrentasvir for 8 weeks in patients with compensated cirrhosis: Safety and effectiveness data from the German Hepatitis Registry. <i>Liver International</i> , 2021, 41, 1518-1522.	1.9	9
34	Impact of HBeAg on Hepatocellular Carcinoma Risk During Oral Antiviral Treatment in Patients With Chronic Hepatitis B. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1343-1353.e16.	2.4	9
35	Low prevalence of occult hepatitis B virus infection in chronic haemodialysis and kidney transplant patients. <i>Liver International</i> , 2019, 39, 263-270.	1.9	7
36	Elevated liver enzymes predict morbidity and mortality despite antiviral cure in patients with chronic hepatitis C: Data from the German Hepatitis Registry. <i>Hepatology Communications</i> , 2022, 6, 2488-2495.	2.0	6

#	ARTICLE	IF	CITATIONS
37	Predictive performance of newer Asian hepatocellular carcinoma risk scores in treated Caucasians with chronic hepatitis B. JHEP Reports, 2021, 3, 100290.	2.6	5
38	Repeated percutaneous hepatic perfusion with melphalan can maintain long-term response in patients with liver cancers. CardioVascular and Interventional Radiology, 2021, , 1.	0.9	5
39	Early Detection of Hepatitis E Virus Ribavirin Resistance Using Next-Generation Sequencing. Antimicrobial Agents and Chemotherapy, 2019, 64, .	1.4	4
40	Final safety and efficacy results from a 106 real-world patients registry with an ascitesâ€mobilizing pump. Liver International, 2022, 42, 2247-2259.	1.9	4
41	Surrogate Markers for Hepatitis B Virus Covalently Closed Circular DNA. Seminars in Liver Disease, 2022, 42, 327-340.	1.8	1